A Retrospective Study of Systemic Treatment of Severe Atopic Dermatitis With Azathioprine: Effectiveness and Tolerance in 11 Pediatric Patients.
Estudio retrospectivo del tratamiento sistémico de la dermatitis atópica grave con azatioprina. Eficacia y tolerancia en 11 pacientes pediátricos.
Atopic dermatitis
Atopic eczema
Azathioprine
Azatioprina
Children
Dermatitis atópica
Eccema atópico
Immunosuppressants
Inmunosupresores
Niños
Journal
Actas dermo-sifiliograficas
ISSN: 2173-5778
Titre abrégé: Actas Dermosifiliogr (Engl Ed)
Pays: Spain
ID NLM: 101777537
Informations de publication
Date de publication:
Apr 2019
Apr 2019
Historique:
received:
09
01
2018
revised:
20
04
2018
accepted:
03
06
2018
pubmed:
1
11
2018
medline:
20
12
2019
entrez:
1
11
2018
Statut:
ppublish
Résumé
Atopic dermatitis (AD) is a chronic inflammatory skin disease that typically affects children. Severe forms may have a profound effect on patients' quality of life. Some forms are resistant to conventional treatment and require the use of systemic immunosuppressants such as azathioprine (AZA) to adequately manage the disease. To evaluate the effectiveness and tolerance of AZA in children with severe AD. We performed a retrospective study of children with severe AD treated with AZA between January 2007 and May 2017. We reviewed the cases of 11 patients (6 boys and 5 girls) with a mean age of 13 years (range, 8-18 years). The mean (SD) age at start of treatment was 10.9 (2.2) years (95% CI 8.6-13.1). The mean initial dosage of AZA was 1.8 (0.2) mg/kg/d. We evaluated treatment response after 4 weeks, 12 to 16 weeks, and 6 months. Mean treatment duration was 10.8 (5.7) months. Treatment had to be suspended in 2 patients because of adverse effects. Seven of the 9 remaining patients presented complete or almost complete clearance of the AD after 6 months of treatment. In our experience, AZA is well tolerated and may be considered as a treatment option in children with severe AD resistant to conventional treatment.
Sections du résumé
BACKGROUND
BACKGROUND
Atopic dermatitis (AD) is a chronic inflammatory skin disease that typically affects children. Severe forms may have a profound effect on patients' quality of life. Some forms are resistant to conventional treatment and require the use of systemic immunosuppressants such as azathioprine (AZA) to adequately manage the disease.
OBJECTIVE
OBJECTIVE
To evaluate the effectiveness and tolerance of AZA in children with severe AD.
PATIENTS AND METHODS
METHODS
We performed a retrospective study of children with severe AD treated with AZA between January 2007 and May 2017.
RESULTS
RESULTS
We reviewed the cases of 11 patients (6 boys and 5 girls) with a mean age of 13 years (range, 8-18 years). The mean (SD) age at start of treatment was 10.9 (2.2) years (95% CI 8.6-13.1). The mean initial dosage of AZA was 1.8 (0.2) mg/kg/d. We evaluated treatment response after 4 weeks, 12 to 16 weeks, and 6 months. Mean treatment duration was 10.8 (5.7) months. Treatment had to be suspended in 2 patients because of adverse effects. Seven of the 9 remaining patients presented complete or almost complete clearance of the AD after 6 months of treatment.
CONCLUSION
CONCLUSIONS
In our experience, AZA is well tolerated and may be considered as a treatment option in children with severe AD resistant to conventional treatment.
Identifiants
pubmed: 30376955
pii: S0001-7310(18)30439-3
doi: 10.1016/j.ad.2018.06.014
pii:
doi:
Substances chimiques
Immunosuppressive Agents
0
Azathioprine
MRK240IY2L
Types de publication
Journal Article
Langues
eng
spa
Sous-ensembles de citation
IM
Pagination
227-231Informations de copyright
Copyright © 2018 AEDV. Publicado por Elsevier España, S.L.U. All rights reserved.